TOP HEADLINES

FEATURED STORY

  • Covance joins trial site group to speed up R&D

    Covance, now a division of LabCorp, has signed a two-year partnership with the Society for Clinical Research Sites, joining a growing list of CROs working to improve communication between sponsors and investigators.

Avista buys another pharma contracting biz

Contract drug developer Avista Pharma Solutions bought the manufacturing, development and animal health services business of rival Scynexis, building up its capacity to take a larger share of an expanding market.

Covance and LabCorp open a new R&D center to pool their expertise

Covance, recently acquired by testing giant LabCorp, has opened a new, expanded clinical research unit in Texas, pairing space for trials alongside a planned patient-service center operated by its parent company.

PRA doubles down on the hunt for new R&D talent

PRA Health Sciences, looking to find the next generation of clinical researchers, is dialing up its recruitment pitch in hopes of meeting the escalating demand for CRO-run trials around the world.

Huntingdon and Harlan raise up to $125M to fund their future together

The recently merged Huntingdon Life Sciences and Harlan Laboratories have convinced their investors to commit up to $125 million in equity financing, lining up the cash they'll need to move forward as a joint entity.

Biocon might spin out its CRO after taking it public

Indian drugmaker Biocon is on the road to taking its in-house CRO public, and the company's founder said she's considering making the company an entirely independent operation.

MORE NEWS

From Our Sister Sites

FierceMedicalDevices

Diagnostic assays that usually require a desktop reader that costs several thousand dollars can now be done using a 3-D printed plate that attaches to a smartphone. Even better, the accuracy of the results achieved are comparable to standard laboratory equipment.

FiercePharma

On Monday, Allergan agreed to sell off a $40.5 billion piece of its business, inking a pact to exit the generics space with a sale to Teva Pharmaceutical Industries. But CEO Brent Saunders is already thinking about future buys.